We detected positive PD-L1 status in as much as 25.7% of early-stage EGFR-mutated NSCLC patients, including 7.1% with high PD-L1 expression (TPS ≥ 50%). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.